How a GLP-1 ‘Shadow System’ Puts Patients’ Safety at Risk

Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and patient safety controls to hawk GLP-1 weight-loss drugs outside of the legitimate prescription drug supply chain, according to a new research-based editorial in Annals of Pharmacotherapy.